| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2947 | kp1212 | Novel non-chain terminating nucleoside analog anti-HIV inhibitor |
|
| DCC2948 | Kpt-6604 | Novel selective, orally bioavailable, PAK4 allosteric modulator against triple negative breast cancer |
|
| DCC2949 | Kpu-300 | Novel potent antimicrotubule agent, exhibiting potent cytotoxicity against HT-29 cells by strongly binding to tubulin and inducing microtubule depolymn. |
|
| DCC2950 | Kr-12-a4 | Potent antimicrobial peptide against gram-positive and gram-negative bacteria and relatively high LPS-neutralization activity |
|
| DCC2951 | Kr-25210 | Novel enteroviral replication inhibitor through a non-capsid binding mode with EC 50 values of 2.5, 2.2, and 3.7 μM against hRV B14, A21, and A71, respectively, targeting the replication stages in the virus |
|
| DCC2952 | Kr-31762 | Novel KATP channel opener, exerting cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury |
|
| DCC2953 | Kras(g12c)-in-1 | Novel irreversible inhibitor of KRAS(G12C) |
|
| DCC2954 | Kras4b-in-d14 | Novel specific inhibitor of oncogenic KRAS4b signaling, stabilizing the KRAS4b-PDEδ complex and remarkably decreasing tumor size and triggered apoptosis of tumor cells |
|
| DCC2955 | Kras4b-pdeδ Stabilizer C19 | Novel stabilizer of the KRAS4b-PDEδ complex, decreasing the proliferation of colorectal cancer cells, and increasing apoptosis via decreased activation of oncogenic KRAS4b signaling |
|
| DCC2956 | Krc-108 | Novel potent multi-kinase inhibitor, targeting Ron, Flt3 and TrkA as well as c-Met |
|
| DCC2957 | Krc-327 | Selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity. |
|
| DCC2958 | Krm-ii-08 | Novel potent, non-toxic, blood-brain barrier crossing, α5-GABA A R preferring ligand, enhancing a chloride-anion efflux that induces mitochondrial membrane depolarization and in response, TP53 upregulation and p53, constitutively phosphorylated at S392, c |
|
| DCC2959 | Krn4884 | Potassium channel opener |
|
| DCC2960 | Krn-8602 Hydrochloride | Topo II inhibitor, exhibiting cytotoxic effects against tumour cells |
|
| DCC2961 | Krp-109 | Novel neutrophil elastase (NE) inhibitor, decreasing expression of TGF-ß Signal Related Genes |
|
| DCC2962 | Krp-199 | Highly potent and selective antagonist for the AMPA receptors, exhibiting good neuroprotective effects in vivo |
|
| DCC2963 | Krp-204 | Novel highly selective β3-adrenoceptor agonist being developed for the treatment of diabetes and obesity |
|
| DCC2964 | Ks-133 | Novel Potent and Selective VIPR2 Antagonist, Counteracting Cognitive Decline in a Mouse Model of Psychiatric Disorders |
|
| DCC2965 | Ksc-392-150 | Novel inhibitor of the permeability transition pore (PTP) |
|
| DCC2966 | kscm-1 | Selective ligand of the sigma-1 receptor |
|
| DCC2967 | Kscm-11 | Ligand of the sigma receptor |
|
| DCC2968 | kscm-5 | Ligand of the sigma receptor |
|
| DCC2969 | Ksk120 | Novel inhibitor of transcriptional activity in Chlamydia trachomatis |
|
| DCC2970 | Ksl-128114 | Novel, highly potent, and metabolically stable peptide inhibitor of syntenin, Inhibiting Glioblastoma |
|
| DCC2971 | Kspa-1 | Novel modulator of kinesin spindle protein (KSP)/Eg5, activating KSP-catalyzed ATP hydrolysis in the absence of microtubules yet inhibiting microtubule-stimulated ATP hydrolysis by KSP |
|
| DCC2972 | Kt-182 | Potent and selective inhibitor of ABHD6 |
|
| DCC2973 | Kt2-962 | TXA2/prostaglandin endoperoxide receptor antagonist |
|
| DCC2974 | Kta-439 | Thyroid hormone receptor β (TRβ) selective agonist |
|
| DCC2975 | Ku-2285 | Hypoxic cell radiosensitizer |
|
| DCC2976 | Kufal194 | Novel selective DYRK1A inhibitor |
|
